Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.1 USD | -1.20% |
|
-1.20% | +3.54% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- With an expected P/E ratio at 199.16 and 55.78 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.54% | 423M | - | ||
+5.90% | 71.83B | A | ||
+22.78% | 9.56B | A- | ||
+30.09% | 4.85B | B- | ||
-21.31% | 4.48B | A- | ||
+24.78% | 3.9B | - | ||
+11.03% | 2.01B | - | - | |
-2.11% | 1.99B | B | ||
-36.28% | 1.89B | C- | ||
-43.19% | 1.77B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GUD Stock
- KHTRF Stock
- Ratings Knight Therapeutics Inc.